Precision Medicine in Ovarian Cancer: Understanding the Evolving Role of PARP Inhibitors

Explore recent improvements in the use of PARP inhibitors to treat ovarian cancer with this IME-certified program featuring an on-demand Webcast and downloadable slides.
Ursula Matulonis, MD

ClinicalThought

Now that niraparib is approved in the first-line maintenance therapy setting, how will your treatment of patients with ovarian cancer change?

Ursula Matulonis, MD Released: January 11, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue